Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30+ Lymphoma Patients Who Received Multiple Prior Lines of Treatment
Abstract Brentuximab vedotin (BV), an antibody-drug conjugate that targets CD30, induces high response rates in CD30+ lymphoid malignancies. It is unknown if BV use affects procurement of autologous CD34+ stem cells and hematopoietic engraftment after autologous stem cell transplantation (ASCT). We...
Gespeichert in:
| Veröffentlicht in: | Biology of blood and marrow transplantation 2015-08, Vol.21 (8), p.1529-1531 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1531 |
|---|---|
| container_issue | 8 |
| container_start_page | 1529 |
| container_title | Biology of blood and marrow transplantation |
| container_volume | 21 |
| creator | Afable, Manuel Caimi, Paolo F Hosing, Chitra de Lima, Marcos Khouri, Issa William, Basem M Nieto, Yago Cooper, Brenda W Anderlini, Paolo Gerson, Stanton L Lazarus, Hillard M Champlin, Richard Popat, Uday |
| description | Abstract Brentuximab vedotin (BV), an antibody-drug conjugate that targets CD30, induces high response rates in CD30+ lymphoid malignancies. It is unknown if BV use affects procurement of autologous CD34+ stem cells and hematopoietic engraftment after autologous stem cell transplantation (ASCT). We examined 42 patients treated with BV before mobilization. Median times from diagnosis to transplantation, from initial BV treatment to transplantation, and from last BV treatment to stem cell collection were 21 months (range, 10 to 210), 5 months (range, 1.5 to 16.8), and 30 days (range, 2 to 280), respectively. Mobilization was successful on the first attempt in 38 patients (90.4%). The median number of infused CD34+ cells was 5.46 × 106 /kg (range, 1.65 to 54.78 × 106 /kg). The median times to neutrophil and platelet engraftment were 10 (range, 9 to 13), and 10.5 days (range, 7 to 35), respectively. BV before high-dose chemotherapy–ASCT did not adversely affect peripheral blood stem cell mobilization and subsequent engraftment in a cohort of heavily pretreated patients with CD30+ lymphomas. |
| doi_str_mv | 10.1016/j.bbmt.2015.04.022 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4830276</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1083879115002992</els_id><sourcerecordid>1697213737</sourcerecordid><originalsourceid>FETCH-LOGICAL-c580t-54581510bbc09edce252fe37002cd75b837bfb6ea3e800d315a39db3d21f26ff3</originalsourceid><addsrcrecordid>eNp9Ul2LEzEUHURx19U_4IPkUZDWm6SZD5CFtbp2oWLRVR9DkrnTps5MapKp9hf5N83Qdf14EAK5kHPOvTnnZtljClMKNH--nWrdxSkDKqYwmwJjd7JTKhif5ILnd1MNJZ-URUVPsgchbAGgmJXV_eyEiYoXvCpOsx8L7FR0O2cxWkNW3q2xt9F5Mse2JQvl9xii7dfkKpBLVMHqFolqInpy7VHFDvtIvtm4IS99KofvtlOafMLaJRZJZ_6KwzOyPHS7jesUWaloEy6QzxtH3qNBu8eavB3aaHdJeeVt6r20PQbimt8tHmb3GtUGfHRzn2UfL19fzxeT5bs3V_OL5cSIEuJEzERJBQWtDVRYG2SCNcgLAGbqQuiSF7rROSqOJUDNqVC8qjWvGW1Y3jT8LDs_6u4G3Y0CffSqlTufvuUP0ikr_37p7Uau3V7OSg6syJPA0xsB774OyTvZ2WCSl6pHNwRJ86pgNLlfJCg7Qo13IXhsbttQkGPCcivHhOWYsISZTAkn0pM_B7yl_Io0AV4cAZhs2lv0MpjkuMHaejRR1s7-X__8H7ppbW-Nar_gAcPWDb5PAUgqA5MgP4w7Nq4YFcnjqmL8J0yy0HY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1697213737</pqid></control><display><type>article</type><title>Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30+ Lymphoma Patients Who Received Multiple Prior Lines of Treatment</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Afable, Manuel ; Caimi, Paolo F ; Hosing, Chitra ; de Lima, Marcos ; Khouri, Issa ; William, Basem M ; Nieto, Yago ; Cooper, Brenda W ; Anderlini, Paolo ; Gerson, Stanton L ; Lazarus, Hillard M ; Champlin, Richard ; Popat, Uday</creator><creatorcontrib>Afable, Manuel ; Caimi, Paolo F ; Hosing, Chitra ; de Lima, Marcos ; Khouri, Issa ; William, Basem M ; Nieto, Yago ; Cooper, Brenda W ; Anderlini, Paolo ; Gerson, Stanton L ; Lazarus, Hillard M ; Champlin, Richard ; Popat, Uday</creatorcontrib><description>Abstract Brentuximab vedotin (BV), an antibody-drug conjugate that targets CD30, induces high response rates in CD30+ lymphoid malignancies. It is unknown if BV use affects procurement of autologous CD34+ stem cells and hematopoietic engraftment after autologous stem cell transplantation (ASCT). We examined 42 patients treated with BV before mobilization. Median times from diagnosis to transplantation, from initial BV treatment to transplantation, and from last BV treatment to stem cell collection were 21 months (range, 10 to 210), 5 months (range, 1.5 to 16.8), and 30 days (range, 2 to 280), respectively. Mobilization was successful on the first attempt in 38 patients (90.4%). The median number of infused CD34+ cells was 5.46 × 106 /kg (range, 1.65 to 54.78 × 106 /kg). The median times to neutrophil and platelet engraftment were 10 (range, 9 to 13), and 10.5 days (range, 7 to 35), respectively. BV before high-dose chemotherapy–ASCT did not adversely affect peripheral blood stem cell mobilization and subsequent engraftment in a cohort of heavily pretreated patients with CD30+ lymphomas.</description><identifier>ISSN: 1083-8791</identifier><identifier>EISSN: 1523-6536</identifier><identifier>DOI: 10.1016/j.bbmt.2015.04.022</identifier><identifier>PMID: 25937397</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Autologous transplantation ; Brentuximab ; Female ; Hematology, Oncology and Palliative Medicine ; Hematopoietic Stem Cell Transplantation - methods ; Hodgkin Disease - therapy ; Humans ; Immunoconjugates - administration & dosage ; Immunoconjugates - therapeutic use ; Ki-1 Antigen - metabolism ; Male ; Middle Aged ; Mobilization ; Retrospective Studies ; Stem Cells - metabolism ; Transplantation Conditioning - methods ; Young Adult</subject><ispartof>Biology of blood and marrow transplantation, 2015-08, Vol.21 (8), p.1529-1531</ispartof><rights>American Society for Blood and Marrow Transplantation</rights><rights>2015 American Society for Blood and Marrow Transplantation</rights><rights>Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c580t-54581510bbc09edce252fe37002cd75b837bfb6ea3e800d315a39db3d21f26ff3</citedby><cites>FETCH-LOGICAL-c580t-54581510bbc09edce252fe37002cd75b837bfb6ea3e800d315a39db3d21f26ff3</cites><orcidid>0000-0001-9376-9377</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1083879115002992$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25937397$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Afable, Manuel</creatorcontrib><creatorcontrib>Caimi, Paolo F</creatorcontrib><creatorcontrib>Hosing, Chitra</creatorcontrib><creatorcontrib>de Lima, Marcos</creatorcontrib><creatorcontrib>Khouri, Issa</creatorcontrib><creatorcontrib>William, Basem M</creatorcontrib><creatorcontrib>Nieto, Yago</creatorcontrib><creatorcontrib>Cooper, Brenda W</creatorcontrib><creatorcontrib>Anderlini, Paolo</creatorcontrib><creatorcontrib>Gerson, Stanton L</creatorcontrib><creatorcontrib>Lazarus, Hillard M</creatorcontrib><creatorcontrib>Champlin, Richard</creatorcontrib><creatorcontrib>Popat, Uday</creatorcontrib><title>Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30+ Lymphoma Patients Who Received Multiple Prior Lines of Treatment</title><title>Biology of blood and marrow transplantation</title><addtitle>Biol Blood Marrow Transplant</addtitle><description>Abstract Brentuximab vedotin (BV), an antibody-drug conjugate that targets CD30, induces high response rates in CD30+ lymphoid malignancies. It is unknown if BV use affects procurement of autologous CD34+ stem cells and hematopoietic engraftment after autologous stem cell transplantation (ASCT). We examined 42 patients treated with BV before mobilization. Median times from diagnosis to transplantation, from initial BV treatment to transplantation, and from last BV treatment to stem cell collection were 21 months (range, 10 to 210), 5 months (range, 1.5 to 16.8), and 30 days (range, 2 to 280), respectively. Mobilization was successful on the first attempt in 38 patients (90.4%). The median number of infused CD34+ cells was 5.46 × 106 /kg (range, 1.65 to 54.78 × 106 /kg). The median times to neutrophil and platelet engraftment were 10 (range, 9 to 13), and 10.5 days (range, 7 to 35), respectively. BV before high-dose chemotherapy–ASCT did not adversely affect peripheral blood stem cell mobilization and subsequent engraftment in a cohort of heavily pretreated patients with CD30+ lymphomas.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Autologous transplantation</subject><subject>Brentuximab</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Hodgkin Disease - therapy</subject><subject>Humans</subject><subject>Immunoconjugates - administration & dosage</subject><subject>Immunoconjugates - therapeutic use</subject><subject>Ki-1 Antigen - metabolism</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mobilization</subject><subject>Retrospective Studies</subject><subject>Stem Cells - metabolism</subject><subject>Transplantation Conditioning - methods</subject><subject>Young Adult</subject><issn>1083-8791</issn><issn>1523-6536</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9Ul2LEzEUHURx19U_4IPkUZDWm6SZD5CFtbp2oWLRVR9DkrnTps5MapKp9hf5N83Qdf14EAK5kHPOvTnnZtljClMKNH--nWrdxSkDKqYwmwJjd7JTKhif5ILnd1MNJZ-URUVPsgchbAGgmJXV_eyEiYoXvCpOsx8L7FR0O2cxWkNW3q2xt9F5Mse2JQvl9xii7dfkKpBLVMHqFolqInpy7VHFDvtIvtm4IS99KofvtlOafMLaJRZJZ_6KwzOyPHS7jesUWaloEy6QzxtH3qNBu8eavB3aaHdJeeVt6r20PQbimt8tHmb3GtUGfHRzn2UfL19fzxeT5bs3V_OL5cSIEuJEzERJBQWtDVRYG2SCNcgLAGbqQuiSF7rROSqOJUDNqVC8qjWvGW1Y3jT8LDs_6u4G3Y0CffSqlTufvuUP0ikr_37p7Uau3V7OSg6syJPA0xsB774OyTvZ2WCSl6pHNwRJ86pgNLlfJCg7Qo13IXhsbttQkGPCcivHhOWYsISZTAkn0pM_B7yl_Io0AV4cAZhs2lv0MpjkuMHaejRR1s7-X__8H7ppbW-Nar_gAcPWDb5PAUgqA5MgP4w7Nq4YFcnjqmL8J0yy0HY</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>Afable, Manuel</creator><creator>Caimi, Paolo F</creator><creator>Hosing, Chitra</creator><creator>de Lima, Marcos</creator><creator>Khouri, Issa</creator><creator>William, Basem M</creator><creator>Nieto, Yago</creator><creator>Cooper, Brenda W</creator><creator>Anderlini, Paolo</creator><creator>Gerson, Stanton L</creator><creator>Lazarus, Hillard M</creator><creator>Champlin, Richard</creator><creator>Popat, Uday</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9376-9377</orcidid></search><sort><creationdate>20150801</creationdate><title>Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30+ Lymphoma Patients Who Received Multiple Prior Lines of Treatment</title><author>Afable, Manuel ; Caimi, Paolo F ; Hosing, Chitra ; de Lima, Marcos ; Khouri, Issa ; William, Basem M ; Nieto, Yago ; Cooper, Brenda W ; Anderlini, Paolo ; Gerson, Stanton L ; Lazarus, Hillard M ; Champlin, Richard ; Popat, Uday</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c580t-54581510bbc09edce252fe37002cd75b837bfb6ea3e800d315a39db3d21f26ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Autologous transplantation</topic><topic>Brentuximab</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Hodgkin Disease - therapy</topic><topic>Humans</topic><topic>Immunoconjugates - administration & dosage</topic><topic>Immunoconjugates - therapeutic use</topic><topic>Ki-1 Antigen - metabolism</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mobilization</topic><topic>Retrospective Studies</topic><topic>Stem Cells - metabolism</topic><topic>Transplantation Conditioning - methods</topic><topic>Young Adult</topic><toplevel>online_resources</toplevel><creatorcontrib>Afable, Manuel</creatorcontrib><creatorcontrib>Caimi, Paolo F</creatorcontrib><creatorcontrib>Hosing, Chitra</creatorcontrib><creatorcontrib>de Lima, Marcos</creatorcontrib><creatorcontrib>Khouri, Issa</creatorcontrib><creatorcontrib>William, Basem M</creatorcontrib><creatorcontrib>Nieto, Yago</creatorcontrib><creatorcontrib>Cooper, Brenda W</creatorcontrib><creatorcontrib>Anderlini, Paolo</creatorcontrib><creatorcontrib>Gerson, Stanton L</creatorcontrib><creatorcontrib>Lazarus, Hillard M</creatorcontrib><creatorcontrib>Champlin, Richard</creatorcontrib><creatorcontrib>Popat, Uday</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biology of blood and marrow transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Afable, Manuel</au><au>Caimi, Paolo F</au><au>Hosing, Chitra</au><au>de Lima, Marcos</au><au>Khouri, Issa</au><au>William, Basem M</au><au>Nieto, Yago</au><au>Cooper, Brenda W</au><au>Anderlini, Paolo</au><au>Gerson, Stanton L</au><au>Lazarus, Hillard M</au><au>Champlin, Richard</au><au>Popat, Uday</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30+ Lymphoma Patients Who Received Multiple Prior Lines of Treatment</atitle><jtitle>Biology of blood and marrow transplantation</jtitle><addtitle>Biol Blood Marrow Transplant</addtitle><date>2015-08-01</date><risdate>2015</risdate><volume>21</volume><issue>8</issue><spage>1529</spage><epage>1531</epage><pages>1529-1531</pages><issn>1083-8791</issn><eissn>1523-6536</eissn><abstract>Abstract Brentuximab vedotin (BV), an antibody-drug conjugate that targets CD30, induces high response rates in CD30+ lymphoid malignancies. It is unknown if BV use affects procurement of autologous CD34+ stem cells and hematopoietic engraftment after autologous stem cell transplantation (ASCT). We examined 42 patients treated with BV before mobilization. Median times from diagnosis to transplantation, from initial BV treatment to transplantation, and from last BV treatment to stem cell collection were 21 months (range, 10 to 210), 5 months (range, 1.5 to 16.8), and 30 days (range, 2 to 280), respectively. Mobilization was successful on the first attempt in 38 patients (90.4%). The median number of infused CD34+ cells was 5.46 × 106 /kg (range, 1.65 to 54.78 × 106 /kg). The median times to neutrophil and platelet engraftment were 10 (range, 9 to 13), and 10.5 days (range, 7 to 35), respectively. BV before high-dose chemotherapy–ASCT did not adversely affect peripheral blood stem cell mobilization and subsequent engraftment in a cohort of heavily pretreated patients with CD30+ lymphomas.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25937397</pmid><doi>10.1016/j.bbmt.2015.04.022</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-9376-9377</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-8791 |
| ispartof | Biology of blood and marrow transplantation, 2015-08, Vol.21 (8), p.1529-1531 |
| issn | 1083-8791 1523-6536 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4830276 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Autologous transplantation Brentuximab Female Hematology, Oncology and Palliative Medicine Hematopoietic Stem Cell Transplantation - methods Hodgkin Disease - therapy Humans Immunoconjugates - administration & dosage Immunoconjugates - therapeutic use Ki-1 Antigen - metabolism Male Middle Aged Mobilization Retrospective Studies Stem Cells - metabolism Transplantation Conditioning - methods Young Adult |
| title | Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30+ Lymphoma Patients Who Received Multiple Prior Lines of Treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T10%3A08%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hematopoietic%20Progenitor%20Cell%20Harvesting%20Is%20Feasible%20after%20Treatment%20with%20Brentuximab%20Vedotin%20in%20CD30+%20Lymphoma%20Patients%20Who%20Received%20Multiple%20Prior%20Lines%20of%20Treatment&rft.jtitle=Biology%20of%20blood%20and%20marrow%20transplantation&rft.au=Afable,%20Manuel&rft.date=2015-08-01&rft.volume=21&rft.issue=8&rft.spage=1529&rft.epage=1531&rft.pages=1529-1531&rft.issn=1083-8791&rft.eissn=1523-6536&rft_id=info:doi/10.1016/j.bbmt.2015.04.022&rft_dat=%3Cproquest_pubme%3E1697213737%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1697213737&rft_id=info:pmid/25937397&rft_els_id=1_s2_0_S1083879115002992&rfr_iscdi=true |